Summary & Overview
CPT 88309: Surgical Pathology, Level VI Tissue Examination
CPT code 88309 is a key billing code for Level VI surgical pathology procedures, specifically for the gross and microscopic examination of complex specimens such as those from the tongue, tonsil (for tumor resection), testis, or spermatic cord. This code is nationally significant due to its role in diagnosing and managing serious conditions, including various malignancies. The code is utilized by pathologists in both facility-based laboratories and office settings, reflecting its broad clinical application.
Major payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. Understanding coverage and reimbursement policies for CPT code 88309 is essential for laboratories, pathology groups, and healthcare administrators seeking to ensure compliance and optimize billing practices.
Readers will gain insights into the clinical context of surgical pathology procedures, current policy updates, and relevant benchmarks for CPT code 88309. The publication also highlights associated modifiers, taxonomies, and ICD-10 diagnoses commonly linked to this code, providing a comprehensive overview for stakeholders in the pathology and billing sectors.
CPT Code Overview
CPT code 88309 represents a Level VI surgical pathology procedure involving gross and microscopic examination of specimens from the tongue, tonsil (for tumor resection), or other sites such as the testis or spermatic cord. This code is used in the context of anatomic pathology procedures, where a pathologist evaluates tissue samples to provide critical diagnostic information. The typical site of service includes an anatomic pathology laboratory (facility billed) or an office setting (POS 11) when performed by a pathologist interpreting surgical specimens.
Clinical & Coding Specifications
Clinical Context
A patient presents with a suspected malignant neoplasm involving the tongue, tonsil, or another anatomical site such as the testis or spermatic cord. The surgical team performs a tumor resection, and the excised specimen is sent to the anatomic pathology laboratory. A pathologist conducts a gross and microscopic examination of the specimen to determine the presence, type, and extent of malignancy. The results guide further clinical management, including potential additional surgery, chemotherapy, or radiation therapy. This workflow is typical in cases where definitive diagnosis and staging of cancer are required following surgical removal of tissue.
Coding Specifications
-
Modifiers:
26: Professional Component – Used when only the pathologist's interpretation and report are billed, not the laboratory processing.TC: Technical Component – Used when only the laboratory's specimen processing is billed, not the pathologist's interpretation.59: Distinct Procedural Service – Used to indicate that a procedure or service is distinct or independent from other services performed on the same day.
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Anatomic Pathology & Clinical Pathology |
207ZP0101X | Cytopathology |
207ZP0104X | Forensic Pathology |
These taxonomies represent specialties qualified to perform and interpret surgical pathology procedures.
Related Diagnoses
-
D00.01: Carcinoma in situ of other and unspecified tongue- Relevant for cases where a tumor resection is performed on the tongue to evaluate for carcinoma in situ.
-
C18.0: Malignant neoplasm of cecum- Applicable when a specimen from the cecum is submitted for gross and microscopic examination following tumor resection.
-
C18.2: Malignant neoplasm of ascending colon- Used when the ascending colon is the site of tumor resection and pathology evaluation.
-
C18.3: Malignant neoplasm of hepatic flexure- Pertinent for specimens from the hepatic flexure submitted for surgical pathology.
-
C18.4: Malignant neoplasm of transverse colon- Relevant for tumor resections involving the transverse colon.
-
C18.5: Malignant neoplasm of splenic flexure- Used for pathology evaluation of specimens from the splenic flexure.
-
C18.6: Malignant neoplasm of descending colon- Applicable for cases involving the descending colon.
-
C18.7: Malignant neoplasm of sigmoid colon- Used when the sigmoid colon is the site of tumor resection.
-
C18.8: Malignant neoplasm of overlapping lesion of colon- Relevant for specimens involving overlapping lesions across different segments of the colon.
Each diagnosis code represents a clinical scenario where surgical pathology examination is necessary to confirm malignancy and guide treatment decisions.
Related CPT Codes
-
88305: Level V surgical pathology, gross and microscopic examination- Used for specimens requiring moderate complexity examination; may be used for less complex tissue samples compared to
88309.
- Used for specimens requiring moderate complexity examination; may be used for less complex tissue samples compared to
-
88307: Level V surgical pathology, gross and microscopic examination- Used for specimens of higher complexity than
88305but less than88309; often for major organ resections.
- Used for specimens of higher complexity than
-
88311: Decalcification procedure on a specimen- Used when specimens require decalcification prior to microscopic examination, commonly in bone or calcified tissue samples.
These codes may be used together in workflows where multiple specimens are submitted, or as alternatives depending on specimen complexity and site.
National Reimbursement Benchmarks
For CPT code 88309, the national mean rate for Medicare is $287.28, which is slightly higher than the BUCA (Blue Cross Blue Shield, UnitedHealthcare, Cigna Health, Aetna) average commercial mean rate of $283.63. Blue Cross Blue Shield stands out with the highest mean rate at $333.16, while Cigna Health and BUCA are at the lower end of the commercial spectrum.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna Health exhibits the widest spread at $242.17, indicating substantial variability in rates. UnitedHealthcare has the tightest range at $140.00, suggesting more consistent reimbursement levels. Blue Cross Blue Shield and Medicare also show relatively wide dispersions, at $229.17 and $258.00 respectively.
The table and chart below present a detailed breakdown of national mean rates and percentile benchmarks for each payer.
State Benchmarks
State: AK1 / 51
Alaska Benchmarks
Alaska exhibits a wide spread in reimbursement rates for CPT code 88309, with the highest commercial payer (Aetna) mean rate at $1,022.75 and the lowest (Cigna Health) at $292.59. The rate spread, measured by the difference between the 75th and 25th percentiles, is most pronounced for Aetna ($72.50) and Blue Cross Blue Shield ($465.38), indicating substantial variability in negotiated rates among providers. Medicare and Cigna Health show much narrower spreads, suggesting more consistent payment levels.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher rates, with Aetna's mean rate more than three times the national mean. The table and chart below present the full breakdown of payer-specific rates, highlighting the significant deviation from national benchmarks and the variability across payers within the state.
Key Insights for Alaska
- Aetna is the highest paying payer for CPT 88309 in Alaska, with a mean rate of $1,022.75.
- Medicare is the lowest paying payer, with a mean rate of $276.56, closely followed by Cigna Health at $292.59.
- All commercial payers in Alaska reimburse at rates significantly above their respective national averages, with Aetna's mean rate more than three times the national mean.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.